Biocon's arm, Biocon Pharma Ltd, has secured USFDA approval for its generic Everolimus tablets. This medication aids in treating tuberous sclerosis complex, a rare genetic disorder causing tumors. The approval for 2mg, 3mg, and 5mg strengths bolsters Biocon's drug offerings, providing a new treatment option for adult and pediatric patients with specific TSC-related conditions.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fRySVtg
via IFTTT
No comments:
Post a Comment